Subgroup analysis of the PROFILE 1007 study, which compared crizotinib with chemotherapy for previously treated patients with ALK-positive NSCLC, showed that median PFS was 4.2 and 2.6 months for pemetrexed and docetaxel, respectively [16]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.